Fiera Capital Corp Sells 45,590 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fiera Capital Corp trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 3.4% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,289,820 shares of the company's stock after selling 45,590 shares during the quarter. Fiera Capital Corp owned 1.53% of IDEAYA Biosciences worth $40,861,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its holdings in shares of IDEAYA Biosciences by 5.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company's stock valued at $288,000 after buying an additional 332 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of IDEAYA Biosciences by 22.9% in the 3rd quarter. Amalgamated Bank now owns 2,840 shares of the company's stock valued at $90,000 after buying an additional 530 shares during the last quarter. US Bancorp DE boosted its holdings in shares of IDEAYA Biosciences by 67.2% in the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after buying an additional 689 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of IDEAYA Biosciences by 35.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company's stock valued at $94,000 after buying an additional 796 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock valued at $29,000 after buying an additional 800 shares during the last quarter. 98.29% of the stock is owned by institutional investors.

IDEAYA Biosciences Trading Up 4.3 %

IDYA stock traded up $1.29 during trading hours on Friday, hitting $31.28. 696,273 shares of the stock were exchanged, compared to its average volume of 744,100. The firm has a market capitalization of $2.70 billion, a P/E ratio of -13.42 and a beta of 0.86. The company has a 50-day simple moving average of $32.23 and a two-hundred day simple moving average of $36.70. IDEAYA Biosciences, Inc. has a 12 month low of $27.52 and a 12 month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03. During the same period in the prior year, the firm posted ($0.46) earnings per share. On average, equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IDYA. Cantor Fitzgerald began coverage on IDEAYA Biosciences in a report on Tuesday, October 15th. They issued an "overweight" rating for the company. Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Oppenheimer restated an "outperform" rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Lifesci Capital upgraded IDEAYA Biosciences to a "strong-buy" rating in a research note on Monday, July 29th. Finally, JPMorgan Chase & Co. dropped their price target on IDEAYA Biosciences from $69.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.91.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.